在遗传性出血性telangiectasia中的T-辅助淋巴细胞的亲血管变化
Alexandre Guilhem1,2, Marion Ciudad2, Marie-Hélène Aubriot-Lorton3
1Service de Médecine Interne et Immunologie Clinique, Centre de compétence maladie de Rendu-Osler, Centre Hospitalo-Universitaire Dijon Bourgogne, Dijon, France.
Frontiers in immunology
|December 25, 2023
概括
遗传性出血端膜切除症 (HHT) 涉及T淋巴细胞异常,在HHT患者中增加了亲血管性T细胞和更高的VEGF-A产生. 这些变化可能为HHT提供新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
- 血管生物学 血管生物学
背景情况:
- 遗传性出血端膜炎症 (HHT) 是一种罕见的遗传疾病,影响血管形成.
- 在BMP9/10通路基因 (ENG,ACVRL1,MADH4) 中的突变会导致HHT,导致telangiectases和动脉静脉形.
- T淋巴细胞异常与HHT有关,但仍然不太了解.
研究的目的:
- 为了研究HT患者T淋巴细胞子集的变化.
- 探索T淋巴细胞在HHT病原发生中的作用,特别是在血管生成中.
- 在HHT中识别T淋巴细胞群体内的潜在治疗点.
主要方法:
- 流细胞计用于量化40名HHT患者和20名对照患者的T淋巴细胞子集.
- 免疫制是在HHT患者的皮肤telangiectases上进行的.
- 在刺激后分析了T血管性淋巴细胞 (Tang) 和VEGF-A表达.
主要成果:
- HHT患者表现出增加的亲血管性T细胞子集 (Th2,Th17,Treg) 和效能记忆T辅助细胞的减少.
- 虽然Tang水平相似,但刺激的Tang在HHT患者中显示出更高的VEGF-A产生.
- 在HHT患者中,Th17子集水平与表持续时间正相关.
结论:
- HHT与亲血管性T淋巴细胞变化有关,可能是由内皮细胞驱动的.
- T淋巴细胞可能是HHT中VEGF-A的重要来源.
- 向这些改变的T淋巴细胞可能代表HHT的新治疗策略.
关键词:
Th17 这是一个很好的方法.Th2 Th2 的意思是什么?这就是Treg Treg.在VEGF-A的基础上.效能记忆 T-辅助淋巴细胞的效能记忆遗传性出血性电脉切开症 (telangiectasia) 是一种遗传性出血性电脉切开症.更多相关视频
08:26A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay
Published on: April 12, 2018
8.0K
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
6.0K
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
01:10Mechanism of Angiogenesis
5.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K